BridgeBio Oncology Therapeutics, Inc. Total Assets
BridgeBio Oncology Therapeutics, Inc. total assets. Based on the latest financial reports, BridgeBio Oncology Therapeutics, Inc. (BBOT) holds total assets worth $417.65 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is BridgeBio Oncology Therapeutics, Inc. worth for the company's overall valuation and market capitalisation.
Total Assets of BridgeBio Oncology Therapeutics, Inc. (2021–2025)
Total assets of BridgeBio Oncology Therapeutics, Inc. from 2021 to 2025. This chart illustrates how BridgeBio Oncology Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. See BBOT live share price for real-time trading data and today's change.
BridgeBio Oncology Therapeutics, Inc. - Asset Composition Analysis
BridgeBio Oncology Therapeutics, Inc. Total Assets Breakdown (December 2025)
BridgeBio Oncology Therapeutics, Inc. total assets breakdown as of December 2025. BridgeBio Oncology Therapeutics, Inc.'s total assets of $417.65 Million consist of 94.9% current assets and 5.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 83.3% |
| Accounts Receivable | $386.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how BridgeBio Oncology Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BridgeBio Oncology Therapeutics, Inc. short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BridgeBio Oncology Therapeutics, Inc.'s current assets represent 94.9% of total assets in 2025, an increase from 0.0% in 2021.
- Cash Position: Cash and equivalents constituted 83.3% of total assets in 2025, up from 0.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
BridgeBio Oncology Therapeutics, Inc. Competitors by Total Assets
Key competitors of BridgeBio Oncology Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
BridgeBio Oncology Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.16 | 5.87 | 90.42 |
| Quick Ratio | 6.16 | 5.87 | 90.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $223.24 Million | $117.27 Million | $2.09 Million |
BridgeBio Oncology Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between BridgeBio Oncology Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.01 |
| Latest Market Cap to Assets Ratio | 0.41 |
| Asset Growth Rate (YoY) | 130.6% |
| Total Assets | $448.38 Million |
| Market Capitalization | $184.25 Million USD |
Valuation Analysis
Below Book Valuation: The market values BridgeBio Oncology Therapeutics, Inc.'s assets below their book value (0.41x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: BridgeBio Oncology Therapeutics, Inc.'s assets grew by 130.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BridgeBio Oncology Therapeutics, Inc. (2021–2025)
The table below shows the annual total assets of BridgeBio Oncology Therapeutics, Inc. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $448.38 Million | +130.62% |
| 2024-12-31 | $194.42 Million | +58304.24% |
| 2023-12-31 | $332.89K | +130.25% |
| 2022-12-31 | $144.58K | +0.21% |
| 2021-12-31 | $144.28K | -- |
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients… Read more